Monday, June 20, 2016

South Korea Patent Allowance for Anti-Obesity Pet Vaccines to Braasch Biotech LLC

Braasch Biotech granted Anti-Obesity patent for pets by Korean Intellectual Property
 Office. Commercial utility and novelty for first therapeutic vaccine for use in
 obese dogs, cats and horses.

Garretson, SD, June 11, 2016 --( Braasch Biotech LLC, 
an emerging biopharmaceutical company pioneering a new field 
of anti-somatostatin vaccines, today announced a Notice of Allowance 
was received from the South Korean Intellectual Property Office for Braasch’
s patent entitled “Compositions and methods for enhanced somatostatin
 immunogenicity.” Working in the area of therapeutic vaccines for
 non-infectious conditions, the currently described methods target adult onset obesity.

The Patent Allowance provides claims for the therapeutic treatment for
 obesity in dogs, cats and horses. The source of obesity includes both 
diabetic and non-diabetic causes. The Braasch vaccine technologies, 
like other veterinary vaccines, utilize specific immunological responses 
post-vaccination. In the case of the Braasch vaccine, the endogenous
 hormone somatostatin is targeted. By attenuating the effects
 of this counter-regulatory hormone, a therapeutic effect on obesity is realized.

“Like human obesity, obesity in dogs and cats is at epidemic proportions. 
Although prevention is always the best option, once an animal reaches 
the obese state, owner intervention is necessary for the pet’s continued 
quality of life and longevity. Currently there are no commercially 
available therapeutic treatments for both dogs and cats,” stated 
Jeralyn Kay Haffer, CEO and Chairman of Braasch. “We are now 
pleased the Korean Intellectual Property Office also has recognized the
 vaccine’s novelty and commercial utility in the fight against obesity.”

Braasch’s intellectual property portfolio includes multiple patent families
 with issued or pending claims directed to utility of anti-somatostatin 
vaccine technologies, Somatovac® for multiple metabolic challenges. 
These applications relate to both human and veterinary use of the technologies.

About Braasch Biotech
Braasch Biotech is a biopharmaceutical company with a focus on the 
development and commercialization of innovative products of therapeutic 
approaches utilizing Somatovac® technologies. Currently in the Product
 Pipeline are vaccines for livestock productivity enhancement, increased
 fertility, GH/IGF-1 deficiencies and obesity treatment. To date, Braasch
 has multiple regulatory submissions in progress on the use of vaccines
 in metabolic regulation. Braasch Biotech is a privately held
 biopharmaceutical with corporate offices in South Dakota.
email or

Contact Information
Jeralyn Kay Haffer
CEO and Chairman
Tel. 605-376-8752
Fax. 605-594-6256

No comments:

Post a Comment